Zynex Announces Arrival of Steven Dyson as CEO and Appointment of New Leadership in Key Roles
Zynex (NASDAQ: ZYXI), a medical technology company focused on non-invasive medical devices, has announced significant leadership changes with the arrival of Steven Dyson as CEO and several key executive appointments effective August 18, 2025.
The new leadership team includes Vikram Bajaj as CFO, bringing 20 years of med-tech sector experience, John T. Bibb as Chief Legal Officer with extensive legal and compliance background, Ajay Gopal as EVP of Sales with proven commercial leadership experience, and Agnes Powell as VP of Billing with 20 years in revenue cycle operations.
The executive leadership team will be completed by existing members Anna Lucsok (COO) and Donald Gregg (President of Zynex Monitoring Solutions). Chairman Thomas Sandgaard expressed confidence in the new team's ability to lead Zynex to new levels of success.
Zynex (NASDAQ: ZYXI), azienda di tecnologie mediche specializzata in dispositivi non invasivi, ha annunciato importanti cambiamenti nella leadership con l'ingresso di Steven Dyson come CEO e l'avvicendamento di diversi dirigenti chiave, a partire dal 18 agosto 2025.
Il nuovo team direttivo comprende Vikram Bajaj come CFO, con 20 anni di esperienza nel settore med-tech, John T. Bibb come Chief Legal Officer con un solido background in ambito legale e compliance, Ajay Gopal come EVP Sales con comprovata esperienza commerciale, e Agnes Powell come VP Billing con 20 anni di esperienza nelle operazioni del ciclo dei ricavi.
Il team esecutivo sarà completato dai membri già in carica, Anna Lucsok (COO) e Donald Gregg (President di Zynex Monitoring Solutions). Il presidente Thomas Sandgaard ha espresso fiducia nella capacità del nuovo gruppo di guidare Zynex verso nuovi traguardi.
Zynex (NASDAQ: ZYXI), una compañía de tecnología médica centrada en dispositivos no invasivos, ha anunciado cambios significativos en su dirección con la incorporación de Steven Dyson como CEO y varias designaciones ejecutivas clave con efecto a partir del 18 de agosto de 2025.
El nuevo equipo directivo incluye a Vikram Bajaj como CFO, con 20 años de experiencia en el sector med-tech, a John T. Bibb como Chief Legal Officer con amplia experiencia en asuntos legales y de cumplimiento, a Ajay Gopal como EVP de Ventas con probada experiencia comercial, y a Agnes Powell como VP de Facturación con 20 años en operaciones del ciclo de ingresos.
El equipo ejecutivo se completará con los miembros actuales Anna Lucsok (COO) y Donald Gregg (President de Zynex Monitoring Solutions). El presidente Thomas Sandgaard expresó su confianza en la capacidad del nuevo equipo para llevar a Zynex a nuevos niveles de éxito.
Zynex (NASDAQ: ZYXI), 비침습적 의료기기 분야의 의료기술 회사가 Steven Dyson을 CEO로 맞이하고 2025년 8월 18일부로 여러 주요 임원 인사를 단행하며 중대한 리더십 변화를 발표했습니다.
신임 경영진은 20년의 메드테크 경력을 보유한 Vikram Bajaj를 CFO로, 법무·컴플라이언스 분야에 풍부한 경험이 있는 John T. Bibb를 Chief Legal Officer로, 검증된 상업적 리더십을 가진 Ajay Gopal를 EVP of Sales로, 수익 사이클 운영 분야에서 20년의 경험을 가진 Agnes Powell를 VP of Billing으로 포함합니다.
기존 임원인 Anna Lucsok(COO)와 Donald Gregg(Zynex Monitoring Solutions 사장)가 경영진을 완성합니다. 이사회 의장 Thomas Sandgaard는 새로운 팀이 Zynex를 새로운 성공 단계로 이끌 것이라고 자신감을 표명했습니다.
Zynex (NASDAQ: ZYXI), entreprise de technologie médicale spécialisée dans les dispositifs non invasifs, a annoncé d'importants changements de direction avec l'arrivée de Steven Dyson en tant que CEO et plusieurs nominations exécutives clés effectives au 18 août 2025.
La nouvelle équipe dirigeante comprend Vikram Bajaj comme CFO, fort de 20 ans d'expérience dans le secteur med-tech, John T. Bibb comme Chief Legal Officer avec une solide expérience en droit et conformité, Ajay Gopal comme EVP des Ventes doté d'une expérience commerciale avérée, et Agnes Powell comme VP Facturation avec 20 ans dans les opérations du cycle des revenus.
L'équipe exécutive sera complétée par les membres actuels Anna Lucsok (COO) et Donald Gregg (President de Zynex Monitoring Solutions). Le président Thomas Sandgaard s'est dit confiant dans la capacité de cette nouvelle équipe à conduire Zynex vers de nouveaux succès.
Zynex (NASDAQ: ZYXI), ein Medizintechnikunternehmen, das sich auf nicht-invasive Geräte spezialisiert, hat bedeutende Führungswechsel bekanntgegeben: Steven Dyson übernimmt die Position des CEO, und mehrere Schlüsselpositionen treten am 18. August 2025 in Kraft.
Zum neuen Führungsteam zählen Vikram Bajaj als CFO mit 20 Jahren Erfahrung im Med-Tech-Bereich, John T. Bibb als Chief Legal Officer mit umfassendem Rechts- und Compliance-Hintergrund, Ajay Gopal als EVP Sales mit nachgewiesener kommerzieller Führungskompetenz und Agnes Powell als VP Billing mit 20 Jahren Erfahrung im Revenue-Cycle-Management.
Das Führungsteam wird durch die bestehenden Mitglieder Anna Lucsok (COO) und Donald Gregg (President von Zynex Monitoring Solutions) komplettiert. Vorsitzender Thomas Sandgaard äußerte sein Vertrauen in die Fähigkeit des neuen Teams, Zynex zu neuen Erfolgen zu führen.
- Strategic strengthening of executive team with experienced industry leaders
- New CEO and leadership team bring extensive med-tech sector expertise
- Comprehensive restructuring of key positions indicates commitment to organizational improvement
- Acknowledgment of need to improve business performance in coming quarters
- Multiple simultaneous leadership changes may create temporary operational disruption
Insights
Complete leadership overhaul at Zynex brings in seasoned med-tech executives with strong backgrounds, signaling potential strategic shift.
Zynex has executed a comprehensive leadership transformation with newly appointed CEO Steven Dyson officially taking the helm alongside four key executive appointments. This wholesale C-suite restructuring brings significant med-tech industry experience to the organization, particularly from companies like Kinetic Concepts (KCI) and Vyaire Medical, suggesting a potential strategic pivot.
The incoming team's credentials are particularly noteworthy. New CFO Vikram Bajaj brings 20+ years of finance leadership with specialized experience in M&A and capital markets within med-tech, potentially signaling future acquisition strategies. Similarly, CLO John Bibb's background spans complex litigation, compliance remediation, and M&A execution - suggesting the company may be addressing underlying governance or compliance concerns.
The appointment of Ajay Gopal as EVP of Sales directly targets commercial execution, while Agnes Powell's selection as VP of Billing specifically addresses revenue cycle operations - both critical functions for a medical device company dependent on insurance reimbursements. The press release subtly hints at previous challenges with a stated commitment to "improve business performance" and "renewing our commitment to the highest integrity in our business practices."
Notably, founder Thomas Sandgaard has moved to Chairman while maintaining board support for the incoming team. This clean break in operational leadership while preserving founder influence typically indicates a deliberate governance reset aimed at performance improvement without completely abandoning institutional knowledge.
On June 30, 2025, the Company announced the Board's appointment of Steven Dyson as the incoming CEO. Since that time, Mr. Dyson and Thomas Sandgaard, the Chairman of the Board, have been actively working with the Board of Directors to round out the executive team and several critical leadership roles within the company. Today the Company is announcing the addition of the following individuals, all of whom have started with the company as of August 18, 2025.
- Vikram Bajaj, Chief Financial Officer
- John T. Bibb, Chief Legal Officer
- Ajay Gopal, EVP of Sales
- Agnes Powell, VP of Billing
Vikram Bajaj joins as Chief Financial Officer with over 20 years of leadership experience in finance, M&A, and strategy within the med-tech sector. Previously, he served as CFO of Vyaire Medical, CFO of Kepro, and as Head of Corporate Development at Kinetic Concepts (KCI). Earlier in his career, Vikram was an investment banker at J.P. Morgan in
John Bibb, our new Chief Legal Officer, is a seasoned executive leader with over 20 years' experience in legal, compliance and HR roles in the med-tech sector, including roles with Kinetic Concepts, Inc., LifeCell, and most recently Vyaire Medical. He has served as an executive leader with companies in private and public environments through M&A, capital markets, complex litigation, government disputes, compliance remediation, and intellectual property exploitation. In his new role, Mr. Bibb will be responsible for the Company's Legal, HR, Compliance and Communications functions.
Ajay Gopal, our new EVP of Sales, is a proven commercial leader in the healthcare and medical device sectors, with prior successful roles at KCI, Danaher, and Healthium Medtech. He is known for delivering transformative growth, high‑integrity team leadership, and improving access to impactful products that improve lives.
Agnes Powell, our new VP of Billing, brings 20 years of experience in leading revenue cycle operations, compliance, and managed care contracting across diverse healthcare settings. She has a proven track record of managing billing processes with a strong commitment to integrity and regulatory compliance. Her background spans hospitals, private practices, and billing companies. Agnes has held key roles at HealthOne, Centura Health, and Toxicology Associates, contributing in various capacities.
Steven Dyson's executive leadership team will consist of Messrs. Bajaj and Bibb, together with Anna Lucsok, the Company's COO, and Donald Gregg, President of Zynex Monitoring Solutions. "I am very pleased that we have been able to move quickly to fill critical roles at the Company as we begin to create a new future for all Zynex stakeholders," said Mr. Dyson. "We have a lot to do to improve business performance at the Company over the coming quarters. I believe we now have the right team in place to deliver excellent results in the future, while renewing our commitment to the highest integrity in our business practices and fulfilling our mission to improve the quality of life for patients suffering from debilitating pain and illness."
Thomas Sandgaard, founder and Chairman of the Board, added "The Board is delighted to welcome Steven Dyson as CEO, together with his new executive team to Zynex. We are confident that this group of experienced, proven leaders will take Zynex to new levels of success. The Board and I are looking forward to supporting Steven and the rest of the management team in Zynex's next chapter."
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. our results of operations and the plans, strategies and objectives for future operations; the timing and scope of any potential stock repurchase; and other similar statements.
Words such as "anticipate," "believe," "continue," "could," "designed," "endeavor," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "preliminary," "will," "would" and similar expressions are intended to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products; the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources; the need to keep pace with technological changes; our dependence on the reimbursement for our products from health insurance companies; the outcome of the Tricare payment suspension; our dependence on first party manufacturers to produce our products on time and to our specifications' implementation of our sales strategy including a strong direct sales force, market conditions; economic factors, such as interest rate fluctuations; and other risks described in our filings with the Securities and Exchange Commission.
These and other risks are described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2024, as well as our quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements contained in this press release represent Zynex's views only as of today and should not be relied upon as representing its views as of any subsequent date. Zynex explicitly disclaims any obligation to update any forward-looking statements, except to the extent required by law.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Vikram Bajaj, CFO
ir@zynex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-announces-arrival-of-steven-dyson-as-ceo-and-appointment-of-new-leadership-in-key-roles-302531914.html
SOURCE Zynex, Inc.
FAQ
Who is the new CEO of Zynex (NASDAQ: ZYXI) as of August 2025?
What major leadership changes did Zynex announce in August 2025?
What is Vikram Bajaj's background as Zynex's new CFO?
What are the immediate priorities for Zynex's new management team?
Who comprises Zynex's complete executive leadership team after the new appointments?
